We have observed that cancer participants who have homozygous Met genotype of the BDNF Val66Met polymorphism performed better in the executive function domain, with fewer participants reporting a decrease in BDNF levels at 6-months from baseline if they were carriers of the Met alleles. The gene discussed is BDNF; the disease is cancer.